Single-Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B-Cell Lymphoma.

MedStar author(s):
Citation: Oncologist. 26(9):e1660-e1663, 2021 09.PMID: 34097758Institution: MedStar Washington Hospital Center | Washington Cancer InstituteDepartment: Hematology/Oncology Fellowship | Internal Medicine ResidencyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Antineoplastic Combined Chemotherapy Protocols | *Lymphoma, Large B-Cell, Diffuse | Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use] | Cyclophosphamide/tu [Therapeutic Use] | Doxorubicin/tu [Therapeutic Use] | Humans | Lymphoma, Large B-Cell, Diffuse/dt [Drug Therapy] | Prednisone/tu [Therapeutic Use] | Prognosis | Retrospective Studies | Rituximab/tu [Therapeutic Use] | Vincristine/tu [Therapeutic Use]Year: 2021Local holdings: Available online from MWHC library: 1996 - presentISSN:
  • 1083-7159
Name of journal: The oncologistAbstract: Outcomes of diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from indolent lymphoma, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone are described in retrospective studies. The efficacy of other regimens in transformed or concurrent DLBCL is largely unknown. In this single-center retrospective study, we present characteristics of concurrent and transformed DLBCL and outcomes after dose-adjusted etoposide, vincristine, cyclophosphamide, prednisone, and doxorubicin with rituximab (DA-EPOCH-R) comparative with de novo DLBCL. Of 170 patients with DLBCL, 136 were de novo, 17 were concurrent, and 17 were transformed. Transformed DLBCL had significantly lower complete response rates and progression-free survival (PFS) but similar overall survival (OS) compared with de novo counterpart. There was no significant difference between de novo and concurrent DLBCL regarding response rates, PFS, and OS. DA-EPOCH-R was associated with inferior OS. Thus, intensified treatment with DA-EPOCH-R might not improve outcomes of transformed DLBCL. Copyright (c) 2021 AlphaMed Press.All authors: Baez-Sosa V, Chaturvedi M, Desai S, Hameed R, Shenoy AGOriginally published: Oncologist. 2021 Jun 07Fiscal year: FY2022Fiscal year of original publication: FY2021Digital Object Identifier: ORCID: Date added to catalog: 2021-07-19
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 34097758 Available 34097758

Available online from MWHC library: 1996 - present

Outcomes of diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from indolent lymphoma, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone are described in retrospective studies. The efficacy of other regimens in transformed or concurrent DLBCL is largely unknown. In this single-center retrospective study, we present characteristics of concurrent and transformed DLBCL and outcomes after dose-adjusted etoposide, vincristine, cyclophosphamide, prednisone, and doxorubicin with rituximab (DA-EPOCH-R) comparative with de novo DLBCL. Of 170 patients with DLBCL, 136 were de novo, 17 were concurrent, and 17 were transformed. Transformed DLBCL had significantly lower complete response rates and progression-free survival (PFS) but similar overall survival (OS) compared with de novo counterpart. There was no significant difference between de novo and concurrent DLBCL regarding response rates, PFS, and OS. DA-EPOCH-R was associated with inferior OS. Thus, intensified treatment with DA-EPOCH-R might not improve outcomes of transformed DLBCL. Copyright (c) 2021 AlphaMed Press.

English

Powered by Koha